Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

2.

Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

Anreddy N, Hazlehurst LA.

J Cell Biochem. 2017 Jan;118(1):15-25. doi: 10.1002/jcb.25617. Epub 2016 Jun 21. Review.

3.

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J.

Oncotarget. 2016 May 24;7(21):30712-29. doi: 10.18632/oncotarget.8750.

4.

Myeloma bone disease: Pathophysiology and management.

Silbermann R, Roodman GD.

J Bone Oncol. 2013 Apr 18;2(2):59-69. doi: 10.1016/j.jbo.2013.04.001. eCollection 2013 Jun. Review.

5.

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.

Qiao M, Wu D, Carey M, Zhou X, Zhang L.

PLoS One. 2015 Dec 11;10(12):e0143206. doi: 10.1371/journal.pone.0143206. eCollection 2015.

6.

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N.

Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Epub 2015 Oct 22. Review.

7.

CD44 deficiency inhibits unloading-induced cortical bone loss through downregulation of osteoclast activity.

Li Y, Zhong G, Sun W, Zhao C, Zhang P, Song J, Zhao D, Jin X, Li Q, Ling S, Li Y.

Sci Rep. 2015 Nov 4;5:16124. doi: 10.1038/srep16124.

8.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J.

Oncotarget. 2015 Oct 27;6(33):34329-41. doi: 10.18632/oncotarget.6020.

9.

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Shay G, Hazlehurst L, Lynch CC.

J Mol Med (Berl). 2016 Jan;94(1):21-35. doi: 10.1007/s00109-015-1345-4. Epub 2015 Oct 1. Review.

10.

Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.

Raimondi L, De Luca A, Amodio N, Manno M, Raccosta S, Taverna S, Bellavia D, Naselli F, Fontana S, Schillaci O, Giardino R, Fini M, Tassone P, Santoro A, De Leo G, Giavaresi G, Alessandro R.

Oncotarget. 2015 May 30;6(15):13772-89.

11.

Notch signaling drives multiple myeloma induced osteoclastogenesis.

Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R.

Oncotarget. 2014 Nov 15;5(21):10393-406.

12.

Bone disease in multiple myeloma: pathophysiology and management.

Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P.

Cancer Growth Metastasis. 2014 Aug 10;7:33-42. doi: 10.4137/CGM.S16817. eCollection 2014. Review.

13.

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.

Bam R, Venkateshaiah SU, Khan S, Ling W, Randal SS, Li X, Zhang Q, van Rhee F, Barlogie B, Epstein J, Yaccoby S.

Blood Cancer J. 2014 Aug 1;4:e234. doi: 10.1038/bcj.2014.54.

14.

Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement.

Tosi P.

Scientifica (Cairo). 2013;2013:104546. doi: 10.1155/2013/104546. Epub 2013 Dec 8. Review.

15.

Mechanisms of multiple myeloma bone disease.

Galson DL, Silbermann R, Roodman GD.

Bonekey Rep. 2012 Aug 1;1:135. doi: 10.1038/bonekey.2012.135. eCollection 2012.

16.

Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.

Kyrtsonis MC, Bartzis V, Papanikolaou X, Koulieris E, Georgiou G, Dimou M, Tzenou T, Panayiotidis P.

Appl Clin Genet. 2010 Jul 28;3:41-51. Print 2010.

17.

Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.

André T, Meuleman N, Stamatopoulos B, De Bruyn C, Pieters K, Bron D, Lagneaux L.

PLoS One. 2013;8(3):e59756. doi: 10.1371/journal.pone.0059756. Epub 2013 Mar 21.

18.

Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone.

Kuroshima S, Elliott KW, Yamashita J.

Calcif Tissue Int. 2013 Jun;92(6):576-85. doi: 10.1007/s00223-013-9720-z. Epub 2013 Mar 17.

19.

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S.

Am J Hematol. 2013 Jun;88(6):463-71. doi: 10.1002/ajh.23433. Epub 2013 Mar 28.

20.

Bone marrow microenvironment in multiple myeloma progression.

Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM.

J Biomed Biotechnol. 2012;2012:157496. doi: 10.1155/2012/157496. Epub 2012 Oct 3. Review.

Supplemental Content

Support Center